Other News To Note
Monday, October 24, 2011
Intarcia Therapeutics Inc., of Hayward, Calif., signed a letter of intent with contract research organization Quintiles Transnational Corp., of Research Triangle Park, N.C., to collaborate on the Phase III program for Intarcia's ITCA 650 (DUROS subcutaneous continuous delivery of exenatide). The program aims to demonstrate multiple advancements in GLP-1 therapy for Type II diabetes. Financial terms were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.